Dr. Robert J. Kreitman explains how an experimental CAR T-cell therapy may help patients with relapsed hairy cell leukemia achieve lasting remissions.
|Articles|November 18, 2015
Michael J. Mauro on Questions From Patients With CML
Author(s)Michael J. Mauro
Michael J. Mauro, provides an overview of some of the questions he hears from patients with chronic myeloid leukemia (CML).
Advertisement
Michael J. Mauro, leader, Myeloproliferative Neoplasms Program, Memorial Sloan Kettering Cancer Center, provides an overview of some of the questions he hears from patients with chronic myeloid leukemia (CML).
Advertisement
Related to this article
Dr. Jacqueline Barrientos discussed how collaboration, individualized treatment and patient advocacy helped a 72-year-old man achieve leukemia remission and receive a kidney transplant.
An expert at ESMO 2026 explains how liquid biopsy and ESR1 testing can help guide treatment for people with HR-positive metastatic breast cancer.
Psychiatrist Dr. Yesne Alici of Memorial Sloan Kettering Cancer Center answers questions about family relationships during cancer, from asking for help to talking with children and friends.
After breast cancer at 30, Aisha shares her journey through motherhood, a double mastectomy, body image struggles and the challenges of survivorship.
Emma Halligan found connection at a free New Jersey retreat for women with cancer, which held its annual walk and 5K on Oct. 17.
Diagnosed with leukemia at 8 years old, Harper feared that losing her hair would change who she was. She reflects on body image, confidence and finding a sense of herself during cancer treatment.
Diagnosed with stage 4 breast cancer weeks after giving birth, Eileen Carter explains why getting a second opinion changed the course of her care.
Advertisement
Advertisement
Trending on CURE
1
FDA Approves Talzenna Plus Xtandi in Hormone-Sensitive Prostate Cancer
2
What Liquid Biopsy and ESR1 Mutations Mean in Breast Cancer
3
Working During Cancer Treatment: Your FMLA and ADA Rights
4
FDA Grants Traditional Approval to Keytruda for TMB-H Solid Tumors
5